|
 |
 |
|
| Genomic Tools in Breast Cancer |
|
| Leading the Way towards Personalized Treatment will be a featured official satellite during this year’s EBCC meeting in Vienna. The program will held on Wednesday 21st of March 2012 from 18:45-20:15 at Vienna Exhibition Center, Hall F1. |
|
| MMR testing now offered to qualify patients for Oncotype DX® Colon Cancer Assay |
|
| The Oncotype DX Colon Cancer Assay and MMR can now be ordered at the same time in a convenient one-step process by selecting the Sequential Assay option on the Oncotype DX requisition form. We are pleased to announce the expansion of Genomic Health’s colon cancer laboratory services to include immunohistochemistry (IHC) testing to assess mismatch repair (MMR) status for stage II colon cancer recurrence risk. MMR testing also enables the identification of the patients with T3 MMR-Proficient (MMR-P) tumors, standard risk patients constituting the majority (~70%) of stage II colon cancer in whom the Recurrence Score® provides valuable recurrence risk discrimination not available with conventional clinical and pathologic factors. Results from the recently published QUASAR validation study strongly support a paradigm in which the Oncotype DX Colon Cancer Recurrence Score, MMR status, and T stage are used to determine recurrence risk for individual patients with stage II colon cancer. The QUASAR study results, which are highly consistent with several other published studies, demonstrate that MMR testing is clinically useful for identifying the ~15% of stage II patients with MMR-Deficient (MMR-D) tumor biology who have low recurrence risk. |
|
| Step-by-Step Guide for Getting Oncotype DX assays available in English, German, French, and Italian |
|
| Genomic Health has developed a new brochure to assist you and your office staff in ordering Oncotype DX tests |
| English | French | German | Italian |
|
|
